Li Xiaoyuan, Cheng Yang, Zhu Baorang, Geng Ming, Yan Peng, Hu Mu
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
66526Beijing Jishuitan Hospital, the Fourth Medical College of Peking University, Beijing, China.
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221080993. doi: 10.1177/15330338221080993.
This study aimed to investigate the implication of () polymorphism on the prognosis of anlotinib monotherapy among patients with treatment-refractory advanced nonsmall cell lung cancer (NSCLC). Designed as a retrospective study, this study included a total of 129 patients with treatment-refractory advanced NSCLC who were administered with anlotinib monotherapy. The efficacy of the patients was assessed regularly. The prognosis was performed and adverse reactions during anlotinib administration were collected. Available and appropriate biological specimens of the 129 patients were collected to perform polymorphism analysis and gene mRNA expression analysis accordingly. Association analysis between genotype status of polymorphism and other variables was implemented in univariate and multivariate analysis. Efficacy data indicated that the objective response rate (ORR) and disease control rate (DCR) of the 129 patients with NSCLC who received anlotinib monotherapy was 9.3% (95% CI: 4.9%-15.7%) and 78.3% (95%CI: 70.2%-85.1%), respectively. Additionally, prognostic data suggested that the median progression-free survival (PFS) and overall survival (OS) of the 129 patients with NSCLC were 4.1 months (95%CI: 2.84-5.36) and 10.1 months (95%CI: 8.58-11.62), respectively. Furthermore, polymorphism analysis indicated that polymorphism of 4397T>C in was of clinical significance in the exploratory analysis, which exhibited that the median PFS of patients with TC/CC and TT genotype of 4397T>C polymorphism were 2.8 and 5.0 months, respectively ( = .009). Additionally, patients with TT genotype conferred a superior OS compared with those with TC/CC genotype (median OS: 11.5 vs 7.3 months, = .016). Interestingly, mRNA expression of the gene suggested that mRNA expression of in PBMC specimens of patients with TC/CC genotype was significantly higher than that of patients with TT genotype ( < .001). Anlotinib monotherapy exhibited potential efficacy for patients with treatment-refractory advanced NSCLC. polymorphism 4397T>C might be used as a promising biomarker to predict the survival of patients with NSCLC who received anlotinib administration.
本研究旨在探讨（）基因多态性对难治性晚期非小细胞肺癌（NSCLC）患者安罗替尼单药治疗预后的影响。本研究为回顾性研究，共纳入129例接受安罗替尼单药治疗的难治性晚期NSCLC患者。定期评估患者的疗效。进行预后评估并收集安罗替尼给药期间的不良反应。收集129例患者可用且合适的生物标本，相应地进行（）基因多态性分析和（）基因mRNA表达分析。在单因素和多因素分析中对（）基因多态性的基因型状态与其他变量进行关联分析。疗效数据表明，129例接受安罗替尼单药治疗的NSCLC患者的客观缓解率（ORR）和疾病控制率（DCR）分别为9.3%（95%CI：4.9%-15.7%）和78.3%（95%CI：70.2%-85.1%）。此外，预后数据显示，129例NSCLC患者的中位无进展生存期（PFS）和总生存期（OS）分别为4.1个月（95%CI：2.84-5.36）和10.1个月（95%CI：8.58-11.62）。此外，多态性分析表明，在探索性分析中，（）基因4397T>C多态性具有临床意义，结果显示4397T>C多态性的TC/CC和TT基因型患者的中位PFS分别为2.8个月和5.0个月（P = 0.009）。此外，TT基因型患者的OS优于TC/CC基因型患者（中位OS：11.5个月对7.3个月，P = 0.016）。有趣的是，（）基因的mRNA表达表明，TC/CC基因型患者外周血单个核细胞（PBMC）标本中（）的mRNA表达显著高于TT基因型患者（P < 0.001）。安罗替尼单药治疗对难治性晚期NSCLC患者显示出潜在疗效。4397T>C基因多态性可能作为一种有前景的生物标志物来预测接受安罗替尼治疗的NSCLC患者的生存情况。
